Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
McKesson
Johnson and Johnson
Merck
Baxter

Last Updated: January 20, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,802,152

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 8,802,152
Title:Microporous zirconium silicate for the treatment of hyperkalemia
Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Inventor(s): Keyser; Donald Jeffrey (Southlake, TX), Guillem; Alvaro F. (Lantana, TX)
Assignee: ZS Pharma, Inc. (Coppell, TX)
Application Number:13/371,080
Patent Claims: 1. A particulate pharmaceutical cation exchange composition comprising a zirconium silicate of formula (I): A.sub.pM.sub.xZr.sub.1-xSi.sub.nGe.sub.yO.sub.m (I) in ZS-9 form, where A is a potassium ion, sodium ion, rubidium ion, cesium ion, calcium ion, magnesium ion, hydronium ion or mixtures thereof, M is at least one framework metal, wherein the framework metal is hafnium (4+), tin (4+), niobium (5+), titanium (4+), cerium (4+), germanium (4+), praseodymium (4+), terbium (4+) or mixtures thereof, "p" has a value from about 1 to about 20, "x" has a value from 0 to less than 1, "n" has a value from 1 to about 12, "y" has a value from 0 to about 12, "m" has a value from about 3 to about 36 and 1.ltoreq.n+y.ltoreq.12, wherein the particles exhibit a uniform microporous structure and a median particle size of greater than 3 microns and less than 7% of the particles in the composition have a diameter less than 3 microns, and the composition exhibits a sodium content below 12% by weight.

2. The composition of claim 1, wherein the sodium content is less than 6% by weight.

3. The composition of claim 1, wherein the sodium content is between 0.05 to 3% by weight.

4. The composition of claim 1, wherein the sodium content is less than 0.01% by weight.

5. The composition of claim 1, wherein less than 4% of the particles in the composition have a diameter less than 3 microns.

6. The composition of claim 1, wherein the composition exhibits a median particle size of greater than 3 microns and less than 3% of the particles in the composition have a diameter less than 3 microns.

7. The composition of claim 1, wherein the composition exhibits a median particle size of greater than 3 microns and less than 2.5% of the particles in the composition have a diameter less than 3 microns.

8. The composition of claim 1, wherein the composition exhibits a median particle size of greater than 3 microns and less than 2% of the particles in the composition have a diameter less than 3 microns.

9. The composition of claim 1, wherein less than 1% of the particles in the composition have a diameter less than 3 microns.

10. The composition of claim 1, wherein the median particle size ranges from 5 to 1000 microns.

11. The composition of claim 1, wherein the composition exhibits a median particle size in the range of about 5 to about 200 microns.

12. The composition of claim 1, wherein the median particle size ranges from 20 to 100 microns.

13. The composition of claim 1, wherein the composition exhibits an x-ray powder diffraction pattern generated using a copper K-alpha radiation source comprising: a first peak at 2 theta corresponding to a first d-spacing within the range of 2.7-3.5 angstroms, and a second peak at 2 theta corresponding to a second d-spacing within the range of 5.3-6.1 angstroms.

14. The composition of claim 13, wherein the x-ray powder diffraction pattern further comprises: a third peak at 2-theta corresponding to a third d-spacing within the range of 5.9-6.7 angstroms, a fourth peak at 2-theta corresponding to a fourth d-spacing within the range of 2.0-2.8 angstroms, and a fifth peak at 2-theta corresponding to a fifth d-spacing within the range of 1.6-2.4 angstroms, the third, fourth, and fifth peaks each have intensity values that are lower than the first and second intensity values.

15. The composition of claim 13, wherein the composition further exhibits an x-ray powder diffraction pattern generated using a copper K-alpha radiation source with at least a third peak at 2 theta corresponding to a third d-spacing within the range of 5.9-6.7 angstroms, and a fourth peak at 2 theta corresponding to a fourth d-spacing within the range of 2.0-2.8 angstroms, the third peak having the third greatest relative intensity within the diffraction pattern, and the fourth peak having the fourth greatest relative intensity within the diffraction pattern.

16. The composition of claim 15, wherein the composition further exhibits at least a fifth peak at 2 theta corresponding to a fifth d-spacing within the range of 1.6-2.4 angstroms, the fifth peak having the fifth greatest relative intensity within the diffraction pattern.

17. The composition of claim 1, wherein the FTIR spectra of the composition does not include absorption peaks at approximately 764 cm.sup.-1.

18. The composition of claim 1, wherein the composition does not indicate peaks at 2-theta values of d-spacing corresponding to 7.5, 32, or 42.5 angstroms when the x-ray diffraction spectrum is generated using a copper K-alpha radiation source.

19. The composition of claim 1, wherein the particulate pharmaceutical composition is formed into a shaped article.

20. The composition of claim 19, wherein the shaped article is a tablet or capsule.

21. The composition of claim 1, wherein the zirconium silicate has a theoretical formula of: A.sub.2ZrSi.sub.3O.sub.9, wherein A is a mixture of sodium and hydronium ions and wherein the composition has a sodium content below 12% by weight.

22. A powdered pharmaceutical cation exchange composition comprising ZS-9 having an X-ray diffraction pattern generated using a copper K-alpha radiation source of: TABLE-US-00008 d(.ANG.) 5.9-6.7 5.3-6.1 2.7-3.5 2.0-2.8 1.6-2.4

wherein the ZS-9 exhibits a uniform microporous structure and a median particle size of greater than 3 microns and less than 3% of the particles in the composition have a diameter less than 3 microns, and the composition exhibits a sodium content below 12% by weight.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Baxter
McKinsey
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.